Home
/
CRISPR Therapeutics AG
/
Financials
/
Quarterly
CRISPR Therapeutics AG — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that CRISPR Therapeutics AG filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2020
Mar 31, 2020
$157.0K
Apr 28, 2020
Q3
2019
Sep 30, 2019
$211.93M
Oct 28, 2019
Q2
2019
Jun 30, 2019
$318.0K
Jul 29, 2019
Q1
2020
Mar 31, 2019
$328.0K
Apr 28, 2020
Q3
2019
Sep 30, 2018
$563.0K
Oct 28, 2019
Q2
2019
Jun 30, 2018
$1.09M
Jul 29, 2019
Q1
2019
Mar 31, 2018
$1.36M
Apr 29, 2019
Q3
2018
Sep 30, 2017
$2.39M
Nov 7, 2018
Q2
2018
Jun 30, 2017
$3.58M
Aug 7, 2018
Q1
2018
Mar 31, 2017
$2.70M
May 8, 2018
Q3
2017
Sep 30, 2016
$1.55M
Nov 8, 2017
Q2
2017
Jun 30, 2016
$795.0K
Aug 10, 2017
Q1
2017
Mar 31, 2016
$476.0K
May 11, 2017
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$889.0K
Nov 10, 2025
Q2
2025
Jun 30, 2025
$892.0K
Aug 4, 2025
Q1
2025
Mar 31, 2025
$865.0K
May 6, 2025
Q3
2025
Sep 30, 2024
$602.0K
Nov 10, 2025
Q2
2025
Jun 30, 2024
$517.0K
Aug 4, 2025
Q1
2025
Mar 31, 2024
$504.0K
May 6, 2025
Q3
2024
Sep 30, 2023
$0
Nov 5, 2024
Q2
2024
Jun 30, 2023
$70.00M
Aug 5, 2024
Q1
2024
Mar 31, 2023
$100.00M
May 8, 2024
Q3
2023
Sep 30, 2022
$94.0K
Nov 6, 2023
Q2
2023
Jun 30, 2022
$158.0K
Aug 7, 2023
Q1
2023
Mar 31, 2022
$940.0K
May 8, 2023
Q3
2022
Sep 30, 2021
$824.0K
Nov 1, 2022
Q2
2022
Jun 30, 2021
$900.70M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$539.0K
May 9, 2022
Q3
2021
Sep 30, 2020
$148.0K
Nov 3, 2021
Q2
2021
Jun 30, 2020
$44.0K
Jul 29, 2021
Q1
2021
Mar 31, 2020
$157.0K
Apr 27, 2021
Q3
2020
Sep 30, 2019
$211.93M
Oct 28, 2020
Q2
2020
Jun 30, 2019
$318.0K
Jul 27, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($106.44M)
Nov 10, 2025
Q3
2025
Jun 30, 2025
($208.55M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($208.55M)
Aug 4, 2025
Q2
2025
Mar 31, 2025
($136.00M)
Aug 4, 2025
Q3
2025
Mar 31, 2025
($136.00M)
Nov 10, 2025
Q1
2025
Mar 31, 2025
($136.00M)
May 6, 2025
Q3
2025
Sep 30, 2024
($85.94M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($126.41M)
Aug 4, 2025
Q3
2025
Jun 30, 2024
($126.41M)
Nov 10, 2025
Q3
2025
Mar 31, 2024
($116.59M)
Nov 10, 2025
Q1
2025
Mar 31, 2024
($116.59M)
May 6, 2025
Q2
2025
Mar 31, 2024
($116.59M)
Aug 4, 2025
Q3
2024
Sep 30, 2023
($112.15M)
Nov 5, 2024
Q3
2024
Jun 30, 2023
($77.74M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($77.74M)
Aug 5, 2024
Q1
2024
Mar 31, 2023
($53.07M)
May 8, 2024
Q3
2024
Mar 31, 2023
($53.07M)
Nov 5, 2024
Q2
2024
Mar 31, 2023
($53.07M)
Aug 5, 2024
Q3
2023
Sep 30, 2022
($174.55M)
Nov 6, 2023
Q3
2023
Jun 30, 2022
($185.83M)
Nov 6, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($132.06M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($229.32M)
Aug 4, 2025
Q1
2025
Mar 31, 2025
($148.42M)
May 6, 2025
Q3
2025
Sep 30, 2024
($110.13M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($151.26M)
Aug 4, 2025
Q1
2025
Mar 31, 2024
($140.59M)
May 6, 2025
Q3
2024
Sep 30, 2023
($132.41M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($95.22M)
Aug 5, 2024
Q1
2024
Mar 31, 2023
($64.49M)
May 8, 2024
Q3
2023
Sep 30, 2022
($182.39M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($183.26M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($175.97M)
May 8, 2023
Q3
2022
Sep 30, 2021
($128.85M)
Nov 1, 2022
Q2
2022
Jun 30, 2021
$762.62M
Aug 8, 2022
Q1
2022
Mar 31, 2021
($114.54M)
May 9, 2022
Q3
2021
Sep 30, 2020
($92.40M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($80.69M)
Jul 29, 2021
Q1
2021
Mar 31, 2020
($73.59M)
Apr 27, 2021
Q3
2020
Sep 30, 2019
$139.16M
Oct 28, 2020
Q2
2020
Jun 30, 2019
($54.98M)
Jul 27, 2020